Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
46.21
-0.05 (-0.11%)
May 16, 2025, 10:32 AM - Market open
Exelixis Revenue
Exelixis had revenue of $555.45M in the quarter ending March 31, 2025, with 30.62% growth. This brings the company's revenue in the last twelve months to $2.30B, up 24.49% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.30B
Revenue Growth
+24.49%
P/S Ratio
5.73
Revenue / Employee
$2,004,291
Employees
1,147
Market Cap
12.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EXEL News
- 1 day ago - Exelixis: A Notable Quarter - Seeking Alpha
- 1 day ago - Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance - Benzinga
- 2 days ago - Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors - Business Wire
- 2 days ago - Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
- 8 days ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May - Business Wire
- 16 days ago - Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 - Business Wire
- 17 days ago - EXEL Industries: Second quarter 2024–2025 sales down 3.8% - GlobeNewsWire